Compositions for diagnosing kidney diseases and their uses
By analyzing single-nuclear RNA from patients with glomerular diseases, specific gene expression patterns were identified, solving the problem of difficulty in early diagnosis of glomerular diseases in existing technologies and achieving accurate diagnosis and identification of therapeutic targets for glomerular diseases.
Patent Information
- Application Number
- CN202580029189.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-25
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies make it difficult to effectively identify the specific pathological mechanisms of glomerular diseases through single-cell transcriptome analysis, leading to difficulties in the early diagnosis of glomerular diseases.
By analyzing single-nuclear RNA from patients with primary minimal change disease, anti-PLA2R antibody-positive membranous nephropathy, immunoglobulin A nephropathy, and diabetic nephropathy, specific gene expression patterns, including genes with increased and decreased expression, were identified for the diagnosis of kidney diseases.
It provides specific diagnostic biomarkers for glomerular diseases, enabling accurate identification of different glomerular diseases for early diagnosis and identification of potential therapeutic targets.
Smart Images

Figure CN123125346A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to compositions for diagnosing kidney diseases using biomarkers capable of diagnosing kidney diseases, and methods for diagnosing kidney diseases. Background Technology
[0002] Kidney disease is one of the leading causes of increased morbidity and mortality worldwide. Glomerular disease is a type of chronic kidney disease that can progress to end-stage renal failure. Glomerular diseases present with common clinical symptoms, such as loss of renal function or proteinuria, while also exhibiting disease-specific histological features and clinical courses. Therefore, it is difficult to express the various pathophysiological mechanisms of glomerular diseases as an integrated pathway. Thus, it is necessary to investigate disease-specific pathological mechanisms in early stages of glomerular disease and to identify the molecular changes and characteristics of each disease.
[0003] Because the kidney is a complex organ composed of various microstructures and cell types, research methods based on single-cell transcriptome analysis are extremely useful. Currently, single-nuclear RNA analysis (single-nuclear transcriptome analysis, snRNA sequencing, or snRNA-seq) techniques can identify the transcriptome of glomerular cells (e.g., podocytes), which were rarely identified in previous single-cell transcriptome analyses (single-cell RNA-seq, scRNA-seq). Therefore, it has been used in various research (Wu et al (J. Am. Soc. Nephrol. (2019) 30:23-32). However, to date, no studies have reported findings using snRNA-seq technology to analyze the transcriptome of each glomerular disease. Summary of the Invention
[0004] Technical issues Therefore, the inventors performed mononuclear transcriptome analysis on samples obtained from patients with primary minimal change disease (MCD), anti-PLA2R antibody-positive membranous nephropathy (MN), immunoglobulin A nephropathy (IgA nephropathy, IgAN), and diabetic nephropathy (DKD), and compared changes in common genes and disease-specific genes. As a result, the invention was completed by identifying genes with increased expression according to disease and genes with decreased expression specifically in the constituent cells of the glomerulus.
[0005] Problem-solving methods To achieve the above objectives, one aspect of the present invention provides a composition for diagnosing kidney disease, comprising a reagent for measuring the mRNA or protein expression level of any of the genes selected from i) to v) below: 1) Any gene selected from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7 and combinations thereof; ii) Any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2 and combinations thereof; iii) Any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5 and combinations thereof; iv) Any gene selected from SCIN, TMSB4X, ST6GAL1, GNE and combinations thereof; or v) A combination of i) to iv) above.
[0006] Another aspect of the present invention provides a method for providing information for diagnosing kidney disease, comprising: a) measuring the mRNA or protein expression level of any gene selected from i) through v) below, and vi) in a sample isolated from a subject; and b) Kidney disease is diagnosed when the mRNA or protein expression level of any of the genes selected from i) to iv) below is increased compared to the normal control, and the mRNA or protein expression level of the gene selected from vi) below is decreased compared to the normal control: i) any gene selected from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7, and combinations thereof; ii) any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2, and combinations thereof; iii) any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5, and combinations thereof; iv) any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, and combinations thereof; or v) a combination of i) to iv) above; and vi) any gene selected from... Any gene from the group consisting of TPM2, MICAL2, TJP1, ANXA2, DMD, CORO2B, SMAD3, NR4A1, LIMA1, ESYT2, SHB, SAMSN1, SPRED2, IRAK3, IKBKB, NFKBIA, FAAH, ACCA1, ACOX1, PTPN1, PTPRJ, NPR1, CDK6, HADHB, ETFDH, RAP1GAP, RGS6, HSD17B4, DAAM2, ROCK2, TAGEF5, TBC1D1, THBS1, ERBB2, STAT3, and combinations thereof.
[0007] Another aspect of the present invention provides a biomarker for minimal change disease (MCD) comprising any gene selected from LC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7 and combinations thereof.
[0008] Another aspect of the present invention provides a biomarker for membranous nephropathy (MN) comprising any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2, and combinations thereof.
[0009] Another aspect of the present invention provides a biomarker for immunoglobulin A nephropathy (IgAN) comprising any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5, and combinations thereof.
[0010] Another aspect of the present invention provides a biomarker for diabetic nephropathy (DKD) comprising any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, and combinations thereof.
[0011] Beneficial effects of the invention In this invention, single-nuclear transcriptome analysis (snRNA-seq) was performed on kidney tissues from 28 patients with glomerular diseases (including minimal change disease, membranous nephropathy, immunoglobulin A nephropathy, and diabetic nephropathy) and controls. The results showed that most increased gene expression was disease-specific, while decreased gene expression was specific to the cell clusters constituting the glomerulus. In this case, the expression of increased genes was similarly increased in most glomerular cell clusters, exhibiting a cell type-nonspecific expression pattern. Furthermore, the expression of decreased genes was similarly decreased in most glomerular disease groups used in this invention, showing a disease-nonspecific expression trend. The gene expression patterns shown in the single-nuclear transcriptome analysis results for each glomerular disease exhibited differences in disease-related biological pathways. In addition, this invention identified transition cells between podocytes and parietal epithelial cells in the glomerulus, as well as podocytes exhibiting endocytic characteristics. Podocytes and myofibroblasts exhibiting endocytic characteristics are associated with clinical features of glomerular diseases. Therefore, the results of this invention can be used as diagnostic markers for glomerular diseases or as targets for therapeutic agents. Attached Figure Description
[0012] Figure 1 This is a diagram illustrating, as a specific example of the invention, the experimental process of performing mononuclear transcriptome analysis using kidney tissue from each type of human glomerular disease.
[0013] Figure 2This is a UMAP (Uniform Manifold Approximation and Projection) plot, showing clusters of identified cell types after mononuclear transcriptomic analysis of kidney tissue from human glomerular diseases.
[0014] Figure 3 This is a dot plot showing the expression of marker genes by identified cell type after mononuclear transcriptome analysis of kidney tissue from human glomerular diseases. Here, the size of the dots represents the relative expression percentage of the marker genes, and the color of the dots represents the average expression level of the marker genes within each cell type. Red: increased expression; blue: decreased expression.
[0015] Figure 4 This is a bar chart showing the proportion of cell types classified in each glomerular disease after mononuclear transcriptomic analysis using kidney tissue from human glomerular diseases.
[0016] Figure 5 This is a heatmap showing the cell clusters defined in a specific example of the invention and the reference (Lake). et al The correlation of mean gene expression values among cell clusters as defined in *Anatlas of healthy and injured cell states and niches in the human kidney* (2023, *Nature*). PEC: parietal epithelial cells; PT: proximal tubules; TAL: thick ascending limb of the loop of Henle; tL: thin ascending limb of the loop of Henle; CNT: connecting tubules; DCT: distal convoluted tubules; CDPC: collecting duct chief cells; CDIC: collecting duct intercalated cells; VSMC: vascular smooth muscle cells; Fibroblasts: fibroblasts; Endo: endothelial cells; Imm: immune cells; ATL: thin ascending limb; PC: chief cells; IC: intercalated cells; EC: endothelial cells; VSM / P: vascular smooth muscle cells / peripheral cells; FIB: fibroblasts; PapE: papillary apex epithelial cells; NEU: neuronal cells.
[0017] Figure 6 This is a heatmap showing the average expression values of genes with increased co-expression in each cell cluster in diabetic nephropathy (DKD) in specific examples of the present invention, compared with references (Lake). et alThe correlation between DKD (diabetic nephropathy), POD (podocytes), PEC (parietal epithelial cells), PT (proximal tubules), TAL (thick ascending limb of the loop of Henle), tL (thin ascending limb of the loop of Henle), CNT (connecting tubules), DCT (distal convoluted tubules), CDPC (collecting duct chief cells), CDIC (collecting duct intercalated cells), VSMC (vascular smooth muscle cells), Fibroblasts, Endo (endothelial cells), Imm (immune cells), ATL (thin ascending limb), IC (intercalated cells), EC (endothelial cells), VSM / P (vascular smooth muscle cells / pericytes), and FIB (fibroblasts).
[0018] Figure 7 This is a heatmap showing the increased expression of DEGs (differentially expressed genes) in each glomerular disease after mononuclear transcriptomic analysis of kidney tissue from human glomerular diseases (|logFC|>0.25, corrected p<0.05). MCD: Minimal change disease; PLA2R MN: Anti-PLA2R antibody-positive membranous nephropathy; IgAN: IgA nephropathy; DKD: Diabetic nephropathy; POD: podocytes; PEC: parietal epithelial cells; PT: proximal tubules; TAL: thick ascending limb of the loop of Henle; tL: thin loop of Henle; CNT: connecting tubules; DCT: distal convoluted tubules; CDPC: collecting duct chief cells; CDIC: collecting duct intercalated cells; VSMC: vascular smooth muscle cells; FIB: fibroblasts; Endo: endothelial cells; IMM: immune cells.
[0019] Figure 8 It's a bar chart, showing the changes in... Figure 7 Enrichment analysis was performed on the DEGs of the 16 modules indicated in the heatmap, identifying genes with increased expression categorized by their corresponding pathways.
[0020] Figure 9 This is a heatmap showing the reduced expression of DEG (|logFC|>0.25, corrected p<0.05) in each glomerular constituent cell type after mononuclear transcriptomic analysis of kidney tissue from human glomerular disease.
[0021] Figure 10 It's a bar chart, showing the changes in... Figure 9 Enrichment analysis was performed on the DEGs of various modules indicated in the heatmap, identifying genes with reduced expression according to their corresponding pathways.
[0022] Figure 11 This is a UMAP image, in which glomerular cell clusters are classified into subclusters, and the results of hematoxylin-eosin staining of glomeruli.
[0023] Figure 12 It is a violin diagram showing the expression of marker genes in podocytes, transition cells, and parietal epithelial cells (PECs).
[0024] Figure 13 This is a graph showing the results of trajectory analysis (top) and pseudo-time analysis (bottom) of podocytes and parietal epithelial cells (PEC).
[0025] Figure 14 This is a heatmap showing the relative expression of cell proliferation-related genes in podocytes, transition cells, and parietal epithelial cells (PECs).
[0026] Figure 15 The heatmap (left) shows regulators activated by cell type in podocytes, transition cells, and parietal epithelial cells (PECs), and a graph showing the average module score of genes contained in regulators classified as similar patterns by disease. p <0.05, p <0.01, MCD: Minimal Change Disease, MN: Anti-PLA2R Antibody Positive Membranous Nephropathy, IgAN: IgA Nephropathy, DKD: Diabetic Nephropathy.
[0027] Figure 16 This is a graph showing the results of RNA in situ hybridization of NPHS1, ALDH1A2, and CASR in human kidney tissues from control, minimal change disease (MCD), anti-PLA2R antibody-positive membranous nephropathy (MN), IgA nephropathy (IgAN), and diabetic nephropathy (DKD). DAPI: cell nucleus.
[0028] Figure 17 This is a violin plot showing module scores derived from GeoMX digital spatial analyzer data using genes with increased expression for each disease. MCD: Minimal Change Disease, IgAN: IgA Nephropathy, DKD: Diabetic Nephropathy. p <0.0001.
[0029] Figure 18 This is a violin plot showing module scores derived from GeoMX digital spatial analyzer data using genes with reduced expression for each disease. MCD: Minimal Change Disease, IgAN: IgA Nephropathy, DKD: Diabetic Nephropathy. p <0.0001.
[0030] Figure 19This is a Venn diagram showing the number of genes with reduced expression in each glomerular disease within the podocyte cluster. MCD: Minimal change disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0031] Figure 20 The bar chart shows the results of DEG enrichment analysis using DEGs that are co-expressed and reduced in podocyte clusters (top) and DEGs that are specifically expressed and reduced in diabetic nephropathy (DKD) (bottom).
[0032] Figure 21 It is a violin plot showing the module score of the genes with increased expression for each disease in the GeoMX digital spatial analyzer data.
[0033] Figure 22 It is a violin plot showing the module score of the genes with reduced expression for each disease in the GeoMX digital spatial analyzer data.
[0034] Figure 23 The bar chart shows the results of DEG enrichment analysis using DEG with increased expression of anti-PLA2R antibody in membranous nephropathy (MN) in podocyte clusters (top) and DEG with increased expression of anti-IgA nephropathy (IgAN) in IgAN (bottom).
[0035] Figure 24 This is a heatmap showing the relative expression of marker genes related to slit septum (SD), detachment, epithelial-mesenchymal transition (EMT), and regeneration in each glomerular disease within the podocyte cluster. MCD: Minimal change disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0036] Figure 25 This is a UMAP diagram showing podocyte clusters classified by cell type. n Cellular subclusters (=3,774).
[0037] Figure 26 This is a box plot showing the module score containing endocytic marker genes (logFC>0.25, corrected p<0.05) after classifying cells contained in podocyte clusters according to the presence of proteinuria in the source sample. Here, proteinuria is classified according to UPCR (urine protein-to-creatinine ratio) thresholds of 0 and 3.5. p <0.0001.
[0038] Figure 27 It is a violin diagram showing the module score of endocytic marker genes contained in each glomerular disease within the podocyte cluster. p <0.05, p <0.0001, MCD: Minimal Change Disease, MN: Anti-PLA2R Antibody Positive Membranous Nephropathy, IgAN: IgA Nephropathy, DKD: Diabetic Nephropathy.
[0039] Figure 28 This is a diagram showing the results of NPHS1 and LRP2 RNA in situ hybridization in podocyte clusters of human kidney tissue from control, minimal change disease (MCD), anti-PLA2R antibody-positive membranous nephropathy (MN), IgA nephropathy (IgAN), and diabetic nephropathy (DKD). DAPI: cell nucleus.
[0040] Figure 29 This is a UMAP diagram showing the formation of stromal cell clusters ( n =14,171) is the result of clustering into cell subclusters.
[0041] Figure 30 This is a graph showing the results of GSEA on TGF-β signaling-related genes in the control and glomerular disease groups, based on the average gene expression in stromal cell clusters.
[0042] Figure 31 The image is a violin plot showing the module score of the TGF-β signaling pathway in the subclusters of stromal cell clusters. p <0.0001.
[0043] Figure 32 This is a graph showing the results of trajectory analysis by classifying the subclusters of fibroblasts from stromal cell clusters into cell subclusters.
[0044] Figure 33 It's a heatmap, showing the trajectory and time from... Figure 32 The top 50 genes were identified from trajectory analysis.
[0045] Figure 34 This is a heatmap showing the results of DEG analysis for each glomerular disease in fibroblast clusters (fibroblast cluster, medullary fibroblast cluster, myofibroblast cluster, and adaptive fibroblast cluster) using K-means clustering, where the fibroblast cluster is a cellular subcluster of the stromal cell cluster.
[0046] Figure 35 It's a bar chart, showing the... Figure 34 The results of enrichment analysis of modules 1 and 4 in the heatmap. MCD: Minimal change disease, MN: Anti-PLA2R antibody positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0047] Figure 36 This is a box plot showing the module scores of myofibroblast marker genes calculated based on estimated glomerular filtration rate (eGFR) in the fibroblast group. Here, eGFR is categorized according to thresholds of 60 and 90. p <0.05, p <0.01, p <0.0001.
[0048] Figure 37 This is a UMAP diagram showing the endothelial cell clusters ( n =20,255) is the result of clustering into cell subclusters.
[0049] Figure 38 This is a dot plot showing the expression of marker genes for each cell type within each subcluster of cells classified within an endothelial cell cluster. Here, the size of the dots represents the relative expression proportion of the marker genes, and the color of the dots represents the average expression level of the marker genes within each cell type.
[0050] Figure 39 This is a Venn diagram showing the number of genes with increased expression for each glomerular disease in the endothelial cell cluster. MCD: Minimal change disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0051] Figure 40 The bar chart shows the results of DEG enrichment analysis using DEG specifically increased in endothelial cell clusters of anti-PLA2R antibody-positive membranous nephropathy (MN, left) or diabetic nephropathy (DKD, right).
[0052] Figure 41 This is a radar chart showing the analysis of TGF-containing cells in endothelial cell clusters using MsigDB (hallmark). β Module scores for genes related to signaling pathways and module scores including genes related to interferon-α response (for controls and each glomerular disease). MCD: Minimal change disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0053] Figure 42a The image is a violin plot showing the results of module scoring analysis using MsigDB (hallmark) to determine the presence of TGF-β signaling pathway-related genes in each subcluster of the endothelial cell cluster. p <0.05, p <0.01, p <0.0001, MCD: Minimal Change Disease, MN: Anti-PLA2R Antibody Positive Membranous Nephropathy, IgAN: IgA Nephropathy, DKD: Diabetic Nephropathy.
[0054] Figure 42b The image is a violin plot showing the results of module scoring analysis using MsigDB (hallmark) of interferon-α response-related genes contained in each subcluster of the endothelial cell cluster. p <0.05, p <0.01, p <0.0001, MCD: Minimal Change Disease, MN: Anti-PLA2R Antibody Positive Membranous Nephropathy, IgAN: IgA Nephropathy, DKD: Diabetic Nephropathy.
[0055] Figure 43 This is a heatmap showing the results of analyzing the relative expression of interferon-α response-related genes for each glomerular disease in the endothelial cell cluster.
[0056] Figure 44 This is a UMAP diagram showing the cluster of near-end tubules ( n =66,273) is the result of clustering into cell subclusters.
[0057] Figure 45 This is a dot plot showing the expression of marker genes for each cell type within each subcluster of the proximal tubule clusters. Here, the size of the dots represents the relative expression proportion of the marker genes, and the color of the dots represents the average expression level of the marker genes within each cell type.
[0058] Figure 46 This is a graph showing the results of GSEA analysis of Wnt / β-catenin signaling-related genes in the control and glomerular disease groups using MSigDB, based on the average gene expression in the proximal tubule clusters.
[0059] Figure 47 This is a heatmap showing the results of analyzing the relative expression of Wnt / β-catenin signaling-related genes for each glomerular disease in the proximal tubule clusters. MCD: Minimal Change Disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0060] Figure 48 This is a Venn diagram showing the number of genes with increased expression for each glomerular disease in the proximal tubule clusters. MCD: Minimal Change Disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0061] Figure 49 This is a heatmap showing the results of analyzing the relative expression of genes related to endocytosis, hypertrophy, damage, and adaptation in each glomerular disease within the proximal tubule clusters. MCD: Minimal Change Disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy.
[0062] Figure 50 It is a graph showing the results of pseudo-time analysis and trajectory path analysis in proximal tubule clusters, classified by cell subclusters.
[0063] Figure 51 This is a stacked bar chart showing the results of a pseudo-time state analysis of each glomerular disease in the proximal tubule clusters. MCD: Minimal change disease, MN: Anti-PLA2R antibody-positive membranous nephropathy, IgAN: IgA nephropathy, DKD: Diabetic nephropathy. Detailed Implementation
[0064] This invention provides a composition for diagnosing kidney diseases.
[0065] As used herein, the term "diagnosis" refers to the identification of the presence or characteristics of a pathological state. For the purposes of this invention, diagnosis can be interpreted as identifying whether kidney disease has occurred and the type of kidney disease, but is not limited thereto.
[0066] As used in this article, the term "kidney" also refers to the kidney or internal kidney, a bean-shaped excretory organ found in vertebrates. It filters metabolites such as urea and minerals from the blood and excretes them along with water in the form of urine, thereby maintaining body water levels and fluid homeostasis, and regulating blood sugar.
[0067] As used in this article, the term "kidney disease" refers to diseases occurring in the kidneys caused by a variety of factors, including external, internal, and genetic factors. Specifically, kidney disease is a glomerular disease, which can be minimal change disease (MCD), membranous nephropathy (MN), immunoglobulin A nephropathy (IgAN), or diabetic nephropathy (DKD), but is not limited to these.
[0068] As used in this article, the term "glomerulus" refers to the part that makes up the renal corpuscle, the internal organelle of the kidney. It is a coiled bundle of capillaries that aggregate within Bowman's capsule. It is also called a glomerulus. Its diameter is approximately 0.1 mm to 0.2 mm. A portion of the blood plasma is pushed from the glomerulus into Bowman's capsule by osmotic pressure, thus achieving filtration. In this process, small molecular weight substances, such as inorganic salts, amino acids, glucose, urea, and water, are filtered, while large molecular weight substances, such as red blood cells, proteins, and fats, are not filtered. The filtered substances are then transferred to the renal tubules connected to Bowman's capsule.
[0069] As used in this article, the term "glomerular disease" refers to diseases caused by inflammatory or non-inflammatory mechanisms that damage the glomeruli. Among these, diseases in which an inflammatory response occurs in the glomeruli and thereby produces symptoms and signs (i.e., inflammatory glomerular diseases) are called glomerulonephritis.
[0070] As used in this article, the term "minimal change disease (MCD)" refers to a disease that primarily damages podocytes in the kidneys through immune mechanisms. As a primary glomerular disease, it is representative of nephrotic syndrome. Here, nephrotic syndrome is characterized by severe proteinuria, but tissue biopsies appear normal under light microscopy and immunofluorescence.
[0071] As used herein, the term "membranous nephropathy (MN)," also known as membranous glomerulonephropathy, is characterized by thickening of the capillary membrane due to the deposition of immune complexes on the outer surface of the glomerular capillaries. It is a representative glomerular disease occurring in adults. In some patients, only proteinuria is observed without symptoms. Drugs such as mercury, gold, and penicillamine; infections such as hepatitis B virus, syphilis, and malaria; systemic lupus erythematosus; or tumors such as lung cancer and gastric cancer have been reported as antigens. However, in most cases, the causative antigen is unknown. Since antibodies against PLA2R1 (phospholipase A2 receptor 1) have been found in 70%–80% of patients with primary membranous nephropathy (MN), which accounts for the majority of membranous nephropathy cases, it is presumed that it develops due to an autoimmune response against PLA2R1.
[0072] As used in this article, the term "immunoglobulin A nephropathy (IgAN)" refers to a disease characterized by the deposition of immune complexes, primarily immunoglobulin A (IgA), in the glomeruli. It is one of the most common glomerular diseases, primarily affecting late childhood or young adulthood, with a higher incidence in women.
[0073] As used in this article, the term "diabetic nephropathy" refers to a condition in which proteinuria occurs due to damage to the glomeruli of the kidneys caused by diabetes, in the absence of other kidney diseases.
[0074] One aspect of the present invention provides a composition for diagnosing kidney disease, comprising a reagent for measuring the mRNA or protein expression level of any gene selected from i) to v). Here, the gene may be selected from any of the following: i) any gene selected from nitrogen transport-related genes, carboxylic acid transport-related genes, arachidic acid transport-related genes, and combinations thereof; ii) any gene selected from epithelial-mesenchymal transition (EMT)-related genes, mitotic spindle-related genes, interferon-γ response-related genes, and combinations thereof; iii) any gene selected from aldosterone-regulated sodium reabsorption-related genes, Rap1 signaling pathway-related genes, MAPK signaling pathway-related genes, and combinations thereof; iv) any gene selected from actin monomer isolation-related genes, amino sugar metabolism-related genes, N-acetylneuraminic acid metabolism-related genes, and combinations thereof; or v) a combination of i) to iv) above.
[0075] Here, the mRNA or protein expression level of this gene may be increased in kidney disease compared to normal controls. Therefore, this gene can be used as a marker gene for kidney disease. Compositions containing reagents capable of detecting the mRNA or protein expression of any gene can be used for the purpose of diagnosing kidney disease. Kidney disease is as described above.
[0076] As used herein, the term "nitrogen transport" refers to the phenomenon of nitrogen-containing compounds entering, leaving, or moving between cells via specific agents such as transport proteins or pores. In this invention, the nitrogen transport-related gene may be SLC13A1 or SLC36A2.
[0077] As used herein, the term "carboxylic acid transport" refers to the phenomenon of carboxylic acids entering, leaving, or moving between cells via specific agents such as transport proteins or pores. Here, carboxylic acid refers to a substance containing one or more carboxyl groups (COOH) or anions (COO). - Organic acids. In this invention, the carboxylic acid transport-related gene can be SLC13A3 or SLC16A19.
[0078] As used herein, the term "arachidonic acid transport (eicosanoic acid transport)," also known as eicosanoic acid transport, refers to the phenomenon of arachidonic acids (or eicosanoic acids) entering, leaving, or moving between cells via specific agents such as transport proteins or pores. Here, arachidonic acids (or eicosanoic acids) refer to unsaturated C2O4 arachidonic acid metabolites present in various types of cell membranes. 20 Fatty acids. In this invention, the arachidic acid transport-related gene can be SLC22A6 or SLC22A7.
[0079] As used herein, the term "epithelial-mesenchymal transition (EMT)" refers to the process by which epithelial cells transform into mesenchymal cells due to decreased cell polarity and cell-cell adhesion, and increased migration and invasion characteristics. In this invention, the EMT-related gene may be SPP1 or VIM.
[0080] As used herein, the term "mitotic spindle" refers to the structure formed during cell division that separates replicating chromosomes. In this invention, the mitotic spindle-related gene may be TRIO or DST.
[0081] As used herein, the term "interferon-γ response" refers to a response to interferon-γ, which can include any process that results in a change in the state or activity (motor activity, secretion, enzyme production, gene expression, etc.) of a cell or organism due to interferon-γ stimulation. In this invention, the interferon-γ response-related gene may be TAPBP or IFNAR2.
[0082] As used herein, the term "aldosterone-regulated sodium reabsorption" refers to sodium reabsorption regulated by aldosterone. Aldosterone binds to mineralocorticoid receptors (MR) located in the collecting duct cells of the kidney in the nephron to promote sodium reabsorption and potassium excretion. In this invention, the aldosterone-regulated sodium reabsorption-related gene may be HSD11B2 or NR3C2.
[0083] As used herein, the term "Rap1 signaling pathway" refers to a signaling pathway induced by the activation or inactivation of Rap1. Rap1 is a small GTPase that regulates various cellular activities, such as cell adhesion, cell-cell junction formation, and cell polarity. Furthermore, Rap1 is known to regulate the activity of mitogen-activated protein kinase (MAPK). In this invention, the Rap1 signaling pathway-related gene may be MAGI1 or MAGI2.
[0084] As used herein, the term "MAPK signaling pathway" refers to the signaling pathway induced by ERK-1 / 2, JNK-1 / 2 / 3, p38, and ERK-5. MAPK is involved in various cellular functions, including cell survival, growth, differentiation, death, and migration. In this invention, the MAPK signaling-related gene can be ERBB4 or EFNA5.
[0085] As used herein, the term "actin monomer isolation" refers to the selective binding of actin monomers to specific molecules to inhibit the binding and polymerization of actin monomers with other monomers. In this invention, the actin monomer isolation-related gene may be SCIN or TMSB4X.
[0086] As used herein, the term "amino sugar metabolism process" refers to the chemical reaction pathways associated with the metabolism of sugars containing amino groups instead of hydroxyl groups, i.e., amino sugars. In this invention, the gene associated with the amino sugar metabolism process may be ST6GAL1 or GNE.
[0087] In a specific instance, the gene i) can be any gene selected from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7, and combinations thereof. Here, the expression of this gene may be specifically increased in minimal change disease (MCD). Therefore, the gene i) can be used as a marker gene for minimal change disease. Compositions containing reagents capable of detecting the mRNA or protein expression of this gene can be used for the purpose of diagnosing minimal change disease.
[0088] In a specific instance, the gene in ii) can be any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2, and combinations thereof. Here, the expression of this gene may be specifically increased in membranous nephropathy (MN). Therefore, the gene in ii) can be used as a marker gene for membranous nephropathy. Compositions containing reagents capable of detecting the mRNA or protein expression of this gene can be used for the purpose of diagnosing membranous nephropathy.
[0089] In a specific instance, the gene in iii) can be any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5, and combinations thereof. Here, the expression of this gene may be specifically increased in immunoglobulin A nephropathy (IgAN). Therefore, the gene in iii) can be used as a marker gene for immunoglobulin A nephropathy. Compositions containing reagents capable of detecting the mRNA or protein expression of this gene can be used for the purpose of diagnosing immunoglobulin A nephropathy.
[0090] In a specific instance, the gene in iv) can be any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, and combinations thereof. Here, the expression of this gene may be specifically increased in diabetic nephropathy (DKD). Therefore, the gene in iv) can be used as a marker gene for diabetic nephropathy. Compositions containing reagents capable of detecting the mRNA or protein expression of this gene can be used for the purpose of diagnosing diabetic nephropathy.
[0091] The diagnostic composition may further comprise reagents for measuring the mRNA or protein expression levels of the following genes: selected from genes associated with actin binding, cadherin binding, neuraminidase binding, ribococcal hormone receptor (GR) binding, protein phosphorylation amino acid binding, negative regulation of the MAPK cascade, response to cytokines, fatty acid (FA) metabolism, monocarboxylic acid catabolism, negative regulation of cellular processes, peptidyl-tyrosine dephosphorylation, regulation of GTPase activity, FA-β oxidation, regulation of actin cytoskeleton organization, regulation of cell migration, transmembrane receptor tyrosine kinase (RTK) signaling pathway, phosphatidylinositol (PI) mediated signal transduction, phosphorylation, and combinations thereof, or combinations thereof.
[0092] Here, the mRNA or protein expression level of this gene may be reduced in kidney disease compared to normal controls. This gene can be used as a marker gene for kidney disease. Compositions containing reagents capable of detecting the mRNA or protein expression of any gene can be used for the purpose of diagnosing kidney disease. Kidney disease is as described above.
[0093] As used herein, the term "actin binding" refers to binding to actin in monomeric or polymeric form, including actin filaments. In this invention, the actin binding-related gene may be TPM2 or MICAL2.
[0094] As used herein, the term "cadherin binding" refers to binding to cadherin. Here, cadherin is a type I transmembrane protein that plays an important role in cell junctions and is dependent on calcium ions (Ca). 2+ ), and participate in the formation of intercellular adhesion junctions within tissues. In this invention, the cadherin-binding related genes may be TJP1, ANXA2, LIMA1, or ESYT2.
[0095] As used herein, the term "neoprotein binding" refers to binding to neoprotein. Here, neoprotein is a cytoskeletal protein found in muscle, fibroblasts, and epithelial cells that binds to actin to anchor F-actin to the membrane. Neoprotein is used to link integrin adhesion molecules of the cell membrane to the actin cytoskeleton. In this invention, the neoprotein binding-related gene may be DMD or CORO2B.
[0096] As used herein, the term "nuclear GR binding" refers to binding to the glucocorticoid receptor, a nuclear receptor. Here, the glucocorticoid receptor is the receptor for the binding of cortisol and glucocorticoids, expressed in most cells, and regulates the expression of proteins involved in development, metabolism, and immune responses. In this invention, the glucocorticoid receptor-related gene may be SMAD3 or NR4A1.
[0097] As used herein, the term "protein phosphorylated amino acid binding" refers to binding to phosphorylated amino acid residues within a protein. As used herein, protein phosphorylated amino acid binding can be SHB or SAMSN1.
[0098] As used herein, the term "negative regulation of the MAPK cascade" refers to any process that inhibits or reduces the frequency, rate, extent, and activity of MAPK signaling. In this invention, the genes associated with negative regulation of the MAPK cascade may be SPRED2, IRAK3, PTPN1, or PTPRJ.
[0099] As used herein, the term "response to cytokines" refers to any process in which the state or activity (motility, secretion, enzyme production, gene expression, etc.) of a cell or organism is regulated by cytokine stimulation. In this invention, the gene associated with the response to cytokines may be SPRED2, IRAK3, IKBKB, or NFKBIA.
[0100] As used herein, the term "fatty acid metabolism process" refers to the chemical reaction pathways in which fatty acids are broken down (catabolism) or synthesized (anabolism). Fat metabolism includes several interconnected pathways, including fatty acid oxidation (β-oxidation), fatty acid synthesis (lipogenesis), and the synthesis and breakdown of complex lipids such as triglycerides and phospholipids. Energy is produced through fatty acid oxidation. Specifically, in fatty acid catabolism, triglycerides are broken down into free fatty acids and glycerol. The free fatty acids are converted into acyl-CoA and undergo beta-oxidation (β-oxidation) and the TCA cycle (tricarboxylic acid cycle) within the mitochondria to produce energy. In this invention, the genes related to fatty acid metabolism processes may be FAAH or ACCA1.
[0101] As used herein, the term "monocarboxylic acid catabolism" refers to a series of chemical reaction pathways by which monocarboxylic acids (organic acids containing a carboxyl group (-COOH)) are broken down. It comprises the chemical reactions and pathways resulting from the aforementioned breakdown. In this invention, the genes associated with monocarboxylic acid catabolism may be FAAH or ACOX1.
[0102] As used herein, the term "negative regulation of cellular processes" refers to any process that inhibits or reduces the frequency, rate, extent, and activity of cellular activities. It is performed at the cellular level, but is not limited to a single cell, and is intended to include all cellular activities, such as cell-cell interactions. In this invention, the gene associated with negative regulation of cellular processes may be NPR1 or CDK6.
[0103] As used herein, the term "peptidyl-tyrosine dephosphorylation" refers to the process of removing a phosphate group from peptidyl-O-phosphotyrosine to form peptidyl-tyrosine. In this invention, the gene associated with peptidyl-tyrosine dephosphorylation may be PTPN1 or PTPRJ.
[0104] As used herein, the terms "fatty acid β-oxidation (FA-β-oxidation)" or "fatty acid oxidation (FA oxidation)" refer to the oxidation (decomposition) of fatty acids that occur in the mitochondria. Fatty acid β-oxidation refers to the pathway in which fatty acids are completely oxidized to carbon dioxide and water, ultimately producing energy. Here, since fatty acids may not be able to directly enter the mitochondria, they are converted to acyl-CoA and undergo β-oxidation. In this invention, the fatty acid β-oxidation-related genes may be HADHB, ETFDH, HADHB, or HDS17B4.
[0105] As used herein, the term "regulation of GTPase activity" refers to any process that regulates the rate at which GTPases hydrolyze GTP. In this invention, the gene associated with the regulation of GTPase activity may be RAP1GAP, RGS6, RAGEF5, or TBC1D1.
[0106] As used herein, the term "regulation of actin cytoskeleton" refers to any process that regulates the frequency, rate, or extent of the formation, arrangement, or breakdown of the cytoskeleton structure composed of actin filaments and related proteins. In this invention, the gene associated with the regulation of actin cytoskeleton may be DAAM2 or ROCK2.
[0107] As used herein, the term "regulation of cell migration" refers to any process that regulates the frequency, rate, or extent of cell migration. In this invention, the gene associated with the regulation of cell migration may be THBS1 or ROCK2.
[0108] As used herein, the term "transmembrane RTK signaling pathway" refers to a signaling pathway mediated by receptor tyrosine kinases (RTKs). RTKs are cell surface receptors for proteins that regulate various cellular activities, such as growth factors, cytokines, and hormones, and play an important role in regulating these activities. Furthermore, they are known to be involved in the development and progression of various cancers. In this invention, the gene associated with the transmembrane receptor tyrosine kinase signaling pathway may be ERBB2 or STAT3.
[0109] As used herein, the term "phosphatidylinositol-mediated signaling" refers to a series of signal transduction processes that utilize phosphatidylinositol as an intracellular signal transduction mediator. Phosphatidylinositol, also known as inositol phospholipid, is phosphorylated by various kinases. The phosphorylated form of phosphatidylinositol participates in lipid signaling, cell signaling, and membrane transport. In this invention, the gene associated with phosphatidylinositol-mediated signaling may be ERBB2 or STAT3.
[0110] As used herein, the term "phosphorylation" chemically refers to the attachment of a phosphate group to a molecule. Phosphorylation and its reverse reaction, dephosphorylation, participate in a variety of biological reactions. In this invention, the phosphorylation-related gene may be ERBB2 or STAT3.
[0111] In a specific embodiment of the invention, the diagnostic composition may further comprise a reagent for measuring the expression level of any gene selected from TPM2, MICAL2, TJP1, ANXA2, DMD, CORO2B, SMAD3, NR4A1, LIMA1, ESYT2, SHB, SAMSN1, SPRED2, IRAK3, IKBKB, NFKBIA, FAAH, ACCA1, ACOX1, PTPN1, PTPRJ, NPR1, CDK6, HADHB, ETFDH, RAP1GAP, RGS6, HSD17B4, DAAM2, ROCK2, RAGEF5, TBC1D1, THBS1, ERBB2, STAT3, and combinations thereof.
[0112] "Reagents for measuring gene expression levels" refers to tools that can measure gene expression levels at the mRNA or protein level.
[0113] Reagents used to measure gene mRNA expression levels can be primers or probes that specifically bind to the gene's nucleic acid sequence, but are not limited to these. Primers or probes can be used in methods such as polymerase chain reaction (e.g., RT-PCR, competitive RT-PCR, and real-time RT-PCR), RNase protection assays, Northern blotting, and DNA microarray analysis, but are not limited to these.
[0114] A primer is a short nucleic acid sequence with a short free 3' hydroxyl group, which can form a base pair with a complementary template and serve as the starting point for template strand replication. A probe is a nucleic acid fragment such as RNA or DNA, ranging from a few bases to hundreds of bases, which can specifically bind to genes or mRNA. It can be prepared in the form of oligonucleotide probes, single-stranded DNA probes, double-stranded DNA probes, RNA probes, etc., and can be labeled for detection, but is not limited to these forms.
[0115] "Reagents used to measure protein expression levels" refers to reagents used in methods for measuring the expression levels of proteins encoded by genes, and may be antibodies, ligands, or aptamers, but are not limited to these. Antibodies, ligands, or aptamers can be used in methods such as Western blotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistochemical staining, immunoprecipitation assay, FACS analysis, and protein microarray analysis, but are not limited to these.
[0116] An antibody is a protein molecule that specifically binds to an antigenic site on a protein or peptide molecule. Antibodies can be polyclonal or monoclonal. Furthermore, antibodies can include special antibodies such as humanized antibodies, and can include not only the entire antibody but also antibody fragments, as long as they exhibit antigen-binding properties; they are not limited to these categories. A ligand is a substance that specifically binds to a protein and can include receptors. An aptamer is a short-chain DNA or RNA molecule that specifically binds to a target molecule. Its function is similar to that of an antibody, but it is stable due to its composition of nucleic acids.
[0117] Diagnostic kits Another aspect of the present invention provides a kit for diagnosing kidney disease, comprising the diagnostic composition described above. The diagnostic composition and kidney disease are as described above.
[0118] Diagnostic kits can be polymerase chain reaction (PCR) kits, DNA microarray kits, enzyme immunoassay (ELISA) kits, or protein microarray kits, but are not limited to these.
[0119] Methods of providing information Another aspect of the present invention provides a method for providing information for diagnosing kidney disease. Specifically, the method for providing information for diagnosing kidney disease includes: a) measuring the mRNA or protein expression level of a gene selected from any one of i) to v) and vi) below, and in a sample isolated from a subject; and b) diagnosing kidney disease when the mRNA or protein expression level of any one of i) to iv) below is increased compared to a normal control, and the mRNA or protein expression level of the gene vi) below is decreased compared to a normal control. i) any gene selected from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7, and combinations thereof; ii) any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2, and combinations thereof; iii) any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5, and combinations thereof; iv) any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, and combinations thereof; or v) a combination of i) to iv) above; and vi) Selected from any gene in the following groups: TPM2, MICAL2, TJP1, ANXA2, DMD, CORO2B, SMAD3, NR4A1, LIMA1, ESYT2, SHB, SAMSN1, SPRED2, IRAK3, IKBKB, NFKBIA, FAAH, ACCA1, ACOX1, PTPN1, PTPRJ, NPR1, CDK6, HADHB, ETFDH, RAP1GAP, RGS6, HSD17B4, DAAM2, ROCK2, RAGEF5, TBC1D1, THBS1, ERBB2, STAT3, and combinations thereof.
[0120] Here, the mRNA or protein expression level of a gene can be measured using the same method described above.
[0121] Furthermore, the method of providing information may further include c) classifying kidney diseases. Here, when gene expression in samples isolated from subjects (i) is increased compared to normal controls, the disease may be classified as minimal change disease syndrome (MCD); when gene expression in (ii) is increased, the disease may be classified as membranous nephropathy (MN); when gene expression in (iii) is increased, the disease may be classified as immunoglobulin A nephropathy (IgAN); and when gene expression in (iv) is increased, the disease may be classified as diabetic nephropathy (DKD). Gene expression can be mRNA or protein expression.
[0122] Here, in samples from subjects diagnosed with kidney disease, the mRNA or protein expression levels of the vi gene may be reduced compared to normal controls.
[0123] The sample can be tissue or cells isolated from the subject. In this case, the subject can be a mammal with or potentially with kidney disease. Preferably, it can be a human. The tissue can be kidney tissue; in a specific instance, it can be a glomerulus. Furthermore, the cells can be cells isolated from kidney tissue. In a specific instance, they can be cells isolated from a glomerulus.
[0124] biomarkers Another aspect of the present invention provides a biomarker for glomerular diseases. Here, glomerular diseases may be minimal change disease (MCD), membranous nephropathy (MN), immunoglobulin A nephropathy (IgAN), or diabetic nephropathy (DKD).
[0125] Biomarkers for minimal change disease (MCD) may include any gene selected from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7 and combinations thereof.
[0126] Biomarkers for membranous nephropathy (MN) may include any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2, and combinations thereof.
[0127] Biomarkers for immunoglobulin A nephropathy (IgAN) may include any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5, and combinations thereof.
[0128] Biomarkers for diabetic nephropathy (DKD) can include any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, and combinations thereof.
[0129] In addition, each biomarker for glomerular disease may further include any gene selected from TPM2, MICAL2, TJP1, ANXA2, DMD, CORO2B, SMAD3, NR4A1, LIMA1, ESYT2, SHB, SAMSN1, SPRED2, IRAK3, IKBKB, NFKBIA, FAAH, ACCA1, ACOX1, PTPN1, PTPRJ, NPR1, CDK6, HADHB, ETFDH, RAP1GAP, RGS6, HSD17B4, DAAM2, ROCK2, RAGEF5, TBC1D1, THBS1, ERBB2, STAT3, and combinations thereof.
[0130] Embodiments of the present invention The present invention will now be described in more detail through the following embodiments. However, the following embodiments are merely illustrative and the scope of the invention is not limited to these embodiments.
[0131] Experimental Method 1. Sample Collection This study was conducted on patients participating in the KORNERSTONE project.
[0132] Pathologists examined the fresh tissue directly on-site to collect sufficient renal cortex. Any remaining biopsy tissue was immediately cryopreserved on-site using a portable liquid nitrogen tank. The patient was then treated according to standard protocols. After reviewing the diagnostic results, samples suitable for the research purpose were selected from the stored tissue for experimental use. Exclusion criteria included a severely decreased estimated glomerular filtration rate (eGFR) indicating chronic renal failure (e.g., eGFR < 30 mL / min / 1.73 m). 2 Patients with chronic renal failure may experience changes in the overall transcriptomic profile (e.g., fibrotic changes).
[0133] In this study, tissue samples were primarily used from patients with primary minimal change disease (MCD), patients with anti-PLA2R antibody-positive membranous nephropathy (MN) exhibiting significant nephrotic syndrome, patients with immunoglobulin A nephropathy (IgAN), or patients with diabetic nephropathy (DKD) without other pathological manifestations of glomerulonephritis. Furthermore, this study targeted patients meeting specific proteinuria criteria: a urine protein-to-creatinine ratio >3 g / g for MCD, MN, and DKD patients, and >0.5 g / g for IgAN patients, and who were not receiving aggressive immunosuppressive therapy. Ultimately, six patients each with MCD, MN, or IgAN and three patients with DKD were included, and transcriptomic changes in kidney tissue samples from a total of 21 patients with glomerular diseases were analyzed.
[0134] As control kidney tissue, normal renal cortex obtained from total nephrectomy for renal cancer was used. For controls, clinical records were carefully reviewed to exclude patients with diabetic or hypertensive nephropathy, and patients without proteinuria or symptoms of renal obstruction were selected. To minimize potential bias during tissue collection and avoid ischemic injury due to renal artery clipping, a surgical gun biopsy was performed after exposing the patient's kidney during surgery and before renal artery clipping. Throughout this process, tissue was collected avoiding cancerous lesions, and the collected tissue was immediately cryopreserved in a portable liquid nitrogen tank and transported to a central storage system. Kidney tissue samples were used from a total of seven control patients in this study.
[0135] Experimental Method 2. Cell Nucleus Extraction and Single-Cell RNA Sequencing Cell nuclei were extracted from kidney tissue samples by adding protease inhibitors (Sigma-Aldrich) and RNase inhibitors (Promega and Life Technologies) to Nuclei EZ lysis buffer (lysis buffer, Sigma-Aldrich).
[0136] Kidney tissue samples were cut into pieces <2 mm in size, processed with 2 mL of frozen Nuclei EZ lysis buffer, and homogenized using a Dounce homogenizer (Sigma-Aldrich). After homogenization, an additional 2 mL of Nuclei EZ lysis buffer was added, and the mixture was incubated on ice for 5 minutes. The mixture was passed through a 40 μm cell filter (PluriSelect) and then centrifuged at 4 °C and 500 × g for 5 minutes. The cell pellet was resuspended in 4 mL of Nuclei EZ lysis buffer and reacted on ice for 5 minutes. The reaction solution was centrifuged (4 °C, 500 × g) and then resuspended in nuclear dispersion buffer (1 × PBS, 1% bovine serum albumin, 0.1% RNase inhibitor; 10 × Genomics).
[0137] The isolated cell nuclei were stained with DAPI, and the cell count was then performed using a Countess 3 automated cell counter (ThermoFisher). Subsequently, a library was prepared using the Chromium Single Cell 3' Reagent kit v3 (10×Genomics). The library was prepared according to the manufacturer's protocol.
[0138] Experimental Method 3. Single-nucleus transcriptome data analysis The FastQ file was aligned to a human precursor mRNA reference sequence (GRCh38; 10× Cell Ranger reference GRCH38v3.0.0), and downstream analysis was performed using the generated feature-barcode matrix. For the filtered count matrix, gene signatures, and cell barcode data, Seurat objects were created using the CreateSeuratObject function of the R package Seurat (version 4.3.0.1). For quality control, cells expressing fewer than 200 genes or mitochondrial gene expression of 2.5% or higher were excluded, as were genes not expressed in any cells. Double cells were removed using the DoubletFinder package (version 2.0.3), each sample was normalized using the SCTransform package (version 0.3.5), and then all samples were merged.
[0139] To overcome batch effects per sample, the Harmony package (version 0.1.1) was used, and 3,000 genes exhibiting highly variable characteristics were selected to align cells from different samples. Principal component analysis (PCA) was used for cell clustering, and the top 40 principal components were visualized using UMAP (Uniform Manifold Approximation and Projection). Cell types were clustered and annotated using UMAP based on known classical marker genes. In this case, cell clusters with a high proportion of mitochondrial genes and no classical genes were defined as contaminating cells.
[0140] Within each cell cluster, genes showing high expression compared to other cell clusters were selected based on the Wilcoxon rank-sum test in Seurat. In the above procedures, a logarithmic fold change of 0.25 and a Bonferroni-corrected p-value <0.05 were used as criteria. Each cell cluster was annotated based on known classical biomarkers. The proportion of cell types under each disease condition was assessed. Functionally correlated sub-clustering was performed to identify important cell types under each disease state, and DEG (differentially expressed genes) were assessed between diseases. All statistical analyses and graphs were performed using Prism version 9.4.1 and R software version 4.1.3.
[0141] Experimental Method 4. DEG analysis using single-nuclear transcriptome analysis data, gene ontology, and trajectory analysis. To identify the DEG between controls and each disease group, a Wilcoxon signed-rank test was performed using Seurat's "FindMarkers" function. The logarithmic fold change (logFC) of the DEG was calculated using the natural logarithm. The DEG was based on Bonferroni correction. p <0.05 and |logFC|>0.25 are defined. EnrichR was used to perform GSEA (gene set enrichment analysis) on gene sets such as the Gene Ontology Biological Processes database, KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway, and HALLMARK pathway.
[0142] Experimental Method 5. Modular Analysis of DEG DEGs showing either all increased or all decreased expression compared to controls were merged in each disease group. Genes were clustered into 16 modules using the "kmeans_k" function of the R package pheatmap (version 1.0.12). DEGs were included in each module and... Figure 5 and Figure 7 The heatmap indicates that it is a module.
[0143] Experimental Method 6. Gene Set Enrichment Analysis GSEA was performed using the H1 gene set (MSigDB v7.0, Broad Institute) with GSEA software (http: / / software.broadinstitute.org / gsea / index.jsp). The expression data for each sample was calculated using the "average expression" function. The enrichment score for each gene set reflects its distribution within the ranking list and was calculated based on the entire ranking list. The normalized enrichment score (NES) for each gene set was determined, and significantly enriched terms were selected based on a false discovery rate (FDR) < 0.05.
[0144] Experimental Method 7. Pseudo-time Analysis Pseudo-time analysis was performed for each cell type (podocytes, proximal tubules, and fibroblasts) using the R package Monocle 2 (version v2.22.0).
[0145] The `newCellDataSet` function in Monocle 2 is used to create a `CellDataSet` object based on normalized count data. As a gene for cell sorting, corrections are used for each cell type. p Genes expressed at levels <0.05 were identified. Dimensionality reduction was performed using the DDRTree algorithm, and cells were sorted according to pseudo-time using the orderCells function.
[0146] Experimental Method 8. Gene Set Scoring Analysis Gene module scores were calculated using gene sets derived from GSEA. For each gene set, the module was scored using "AddModuleScore". The calculated module scores were visualized using Seurat's VInPlot function, with the median represented by a crosshair.
[0147] Experimental Method 9. Single-cell regulatory network prediction and cluster analysis Transcription factor activity for each cell type was predicted using pySCENIC (version 0.11.2), and transcription factors and co-expressed target genes were derived using GRNboost. Regulators were identified by combining gene expression analysis and DNA motif analysis results. For a comprehensive analysis of individual transcription factors, gene expression, and regulator activity within each cell, the AUC (area under the curve) score was calculated using the AUCell function.
[0148] Experimental Method 10. RNA In Situ Hybridization Each kidney tissue sample was fixed in formalin and then paraffin-embedded tissue sections were prepared. RNA in situ hybridization was performed on the tissue sections using the RNAscope Multiplex Detection Kit V2 (ACD Bio) and the RNAscope 4-Plex Ancillary Kit (ACD Bio). In this case, tissue pretreatment and washing were performed according to the manufacturer's protocol, followed by the use of RNAscope probes. Hs-NPHS1 (#416071-C4), Hs-LRP2 (#532391), Hs-ALDH1A2 (#528741-C2), and Hs-CASR (#411931) were used as RNAscope probes. Additionally, FITC (OPAL 520), TRITC (OPAL 570), Cy 5.5 (OPAL 690), or DAPI were used as fluorescent substances and confirmed using an LSM980 instrument and an Airyscan2 (Carl Zeiss).
[0149] Experimental Method 11. Confirming the reproducibility of mononuclear transcriptome profiles Data were downloaded from the KPMF group website (https: / / www.ncbi.nlm.nih.gov / geo / query / acc.cgi?acc=GSE183277) to confirm the reproducibility of the mononuclear transcriptome analysis results of this invention. In the data, the correlations between cell type-specific marker genes according to the invention were assessed to determine the accuracy of the annotation. Furthermore, since both datasets contain DKD patient samples, correlation analysis was performed on DEGs that are increased under DKD conditions in each cell type for validation.
[0150] Experimental Method 12. Confirming the reproducibility of glomerular transcriptome profiles The reproducibility of the DEGs (definition groups) of glomerular cell populations classified in the snRNA-seq data according to the present invention was confirmed in independent spatial transcriptomic data. Briefly, glomerular transcriptomic analysis was performed on kidney tissue sections from patients with various glomerular diseases using the GeoMX digital spatial analyzer (see doi:10.6084 / m9.figshare.24919956). As a control, biopsies collected immediately after transplantation from transplant recipients (zero-point biopsies) were used. Genes with logFC < -1.0 were selected as DEGs of decreased expression, and the top 25 genes were selected as genes of increased expression. The "AddModuleScore" function was applied to the snRNA-seq data of the present invention for analysis.
[0151] Experimental Method 13. Statistical Analysis The experimental results are expressed as mean statistic ± standard deviation. Statistical significance between groups was calculated using one-way ANOVA and post-hoc comparisons (Tukey's HSD test) in R software version 4.1.3. p A value <0.05 is considered statistically significant between groups.
[0152] Experimental Results 1. Basic Information of Samples This study collected mononuclear transcriptome data from a total of 28 subjects, including 6 patients with primary MCD, 6 patients with myeloid nephropathy (MN), 6 patients with IgAN, 3 patients with diabetic kidney disease (DKD), and 7 controls. The study included patients with primary MCD presenting with significant nephrotic syndrome symptoms, MN patients positive for anti-PLA2R antibodies, IgAN patients, or DKD patients with unconfirmed pathology of other glomerulonephritis, as well as patients without clinically suspected secondary causes. Control kidney samples were obtained from non-cancerous lesions of renal cell carcinoma patients using a biopsy gun prior to surgical clipping of the renal artery, thus minimizing batch effects during sample collection. The mean urine protein / creatinine ratio (UPCR) for each group was: MCD group 6.68 = 3.40 g / g, MN group 7.98 = 6.49 g / g, IgAN group 1.96 = 1.60 g / g, DKD group 4.50 = 0.89 g / g, and no proteinuria was observed in the control group. The mean eGFR of the study participants was 85.4 ± 25.7 mL / min / 1.73 m 2 Each sample exhibited typical clinical features, such as nephrotic syndrome edema in patients with MCD.
[0153] Experimental Results 2. Experimental Design and Cell Type Annotation A total of 262,984 cell nuclei were obtained from biopsy tissue and analyzed. Subsequent analysis identified three types of transcriptomic signatures: i) disease-specific and cell-type-common expression patterns, ii) cell-type-specific and disease-common expression patterns, and iii) cell-type and disease-specific expression patterns. The results were validated using various analytical methods. Figure 1 ).
[0154] Of the obtained nuclei, 216,633 (82.4%) were classified as epithelial cell clusters, 20,255 (7.7%) as endothelial cell clusters, 14,171 (5.4%) as stromal cell clusters, and 3,486 (1.3%) as immune cell clusters. These cell clusters were re-clustered into 13 major cell clusters and annotated based on known marker genes. Specifically, the cell clusters included podocyte clusters, parietal epithelial cell (PEC) clusters, proximal tubule (PT) clusters, thick ascending limb of the loop of Henle (TAL) clusters, thin ascending limb of the loop of Henle (tL) clusters, distal convoluted tubule (DCT) clusters, connecting tubule (CNT) clusters, collecting duct chief cells (CDPC) clusters, collecting duct intercalated cells (CDIC) clusters, endothelial cell clusters, vascular smooth muscle cell (VSMC) clusters, fibroblast clusters, and immune cell clusters. Figure 2 ).
[0155] To validate the data, the relevance was assessed by comparing the results with external datasets from the Kidney Precision Medicine Project (KPMP) group, which provides the largest amount of human kidney snRNA-seq data.
[0156] As a result, the expression profiles of cellular marker genes in this dataset showed a high correlation with the data of this invention. These results confirm that the cell cluster analysis results (annotation results) based on the analysis according to this invention are reliable. Figure 5 On the other hand, papillary tip epithelial cells (PapE) and neuronal cell clusters were not detected in the analysis results according to the present invention. Given that the samples used in this study were collected from renal biopsies of cortical tissue, it is presumed that they do not contain PapE or neuronal cells. Furthermore, both the KPMP dataset and the samples used in this study contain DKD patient samples, and the upregulated DEG showed a similar pattern ( Figure 6 ).
[0157] Experimental Results 3. DEG Analysis of Glomerular Diseases Cluster analysis of the DEGs obtained in this invention revealed that DEGs with increased expression exhibited a pattern of increased expression specificity associated with glomerular diseases, independent of cell type. Conversely, DEGs with decreased expression showed reduced expression specificity at the cell type level but did not exhibit a disease-specific expression pattern.
[0158] Regarding the above results, specific gene modules with increased expression in each cell of each disease were identified ( Figure 7 and Figure 8 ).
[0159] Specifically, transporter-related genes such as SLC13A1, SLC36A2, and SLC16A9 are included in modules with increased specific expression in the MCD (module 13, Figure 8Epithelial-mesenchymal transition (EMT)-related genes such as SPP1 and VIM, and interferon-γ response-related genes such as TAPBP and IFNAR2, are included in modules with increased specific expression in MN (module 16). Figure 8 ).
[0160] As previously reported, the IgAN-specific upregulation module is associated with aldosterone-regulated sodium reabsorption and the Rap1 and MAPK signaling pathways (module 4, Figure 8 ). Modules with increased specific expression in DKD include genes associated with several metabolic processes in various kidney cells (module 11, Figure 8 Furthermore, reduced DEG expression was universally decreased in all four diseases. Figure 9 ).
[0161] The expression of actin-binding related genes (TPM2, MICAL2, etc.) and neomycin-binding related genes (DMD, CORO2B, etc.) is specifically reduced in podocyte clusters (Module 1, Figure 10 The above results indicate that the inability to maintain cell structure due to actin cytoskeleton dysregulation in podocytes is a common pathological change regardless of disease type. Nuclear GR-binding related genes (module 6, ) are contained in modules specifically with reduced expression in collecting duct chief cells (CDPC) clusters. Figure 10 It plays an important role in maintaining renal function. NR4A1, encoding the protein Nur77, has been shown to alleviate renal fibrosis by inhibiting the TGF-β / Smad signaling pathway. SPRED2 is known to prevent epithelial-mesenchymal transition (EMT) and endothelial cell damage by inhibiting MAPK activation. In endothelial cell clusters, SPRED2 expression is specifically reduced, and ontological biological process analysis predicts that the MAPK cascade will be inhibited (Module 8, Figure 10 ).
[0162] Fatty acid β-oxidation is part of fatty acid metabolism and an important process for ATP production in renal tubular epithelial cells. Fatty acid metabolism-related genes are specifically reduced in the proximal tubule (PT) cluster and the thick ascending limb of the loop of Henle (TAL) cluster (modules 12 and 13). Figure 10 In parietal epithelial cell (PEC) clusters, gene expression that inhibits MAPK signaling, known to induce PEC proliferation, was reduced. These results suggest that MAPK signaling may be upregulated during the development of glomerular-related diseases (Module 15). Figure 10 ).
[0163] Experimental Result 4. Analysis of Specific Transitional Cells Connecting Podocytes and Parietal Epithelial Cells The podocyte clusters, parietal epithelial cell (PEC) clusters, mesangial cell clusters, and endothelial cell clusters that make up the glomerulus are classified into six distinct subgroups. Interestingly, a cell cluster called "Transition" was identified during this classification process. The Transition cell cluster is located between the podocytes and PECs in UMAP, connecting the two cell groups (…). Figure 11 It can be confirmed that transitional cell clusters express cell-specific marker genes while simultaneously expressing podocyte and PEC marker genes at intermediate levels. Figure 12 ).
[0164] Furthermore, pseudo-time analysis confirmed that the transitional cell cluster was located between the PEC and podocytes. These results indicate that differentiation is underway. Figure 13 Furthermore, genes that showed high expression in the proliferative PEC clusters identified in previous studies were also similarly increased in the transitional cell clusters. Figure 14 Based on the above results, the transitional cell cluster is considered to represent an intermediate state between PECs and podocytes. Figure 11 and Figure 14 ).
[0165] To identify the differentiation regulation mechanism of transitional cell clusters, changes in transcription factor expression were analyzed using Single Cell Regulatory Network Inference and Clustering (SCENIC) analysis.
[0166] The results confirmed that the expression of a total of 61 transcription factors was regulated in the podocyte cluster, PEC cluster, and transition cell cluster. Figure 15 The module scores of genes regulated by these transcription factors exhibit different patterns among glomerular diseases. Figure 15 The “Mode 6” module showed the highest expression primarily in the control and was also highly expressed in the podocyte cluster. Compared to the control, in MN, IgAN, and DKD, the expression of genes that were primarily highly expressed in the PEC cluster was increased (Modes 1, 2, and 3). In particular, Mode 3 showed significantly higher module scores in all disease categories of MN, IgAN, and DKD compared to the control. Figure 15 Pattern 4 is specifically highly expressed in transitional cell clusters. These genes are regulated by transcription factors NFIB, ESRRB, or GATA3, and their specific increase in IgAN can be confirmed. Figure 15 In the four disease groups, the expression patterns of genes with increased expression in MN, IgAN, or DKD showed similar trends, while MCD showed a gene expression pattern similar to the control. These results confirm that MCD is not associated with podocyte damage or activation of PEC or transitional cell clusters.
[0167] Similar results were also confirmed in the RNA in situ hybridization results. Specifically, the expression locations of podocyte marker genes (NPHS1, ALDH1A2) and PEC marker gene (CASR) were confirmed in tissue samples from each disease group.
[0168] As a result, fusion of marker genes for podocytes and PECs was observed in MN, IgAN, and DKD, but not in the control and MCD. Figure 16 ).
[0169] Furthermore, gene expression data of glomerular constituent cells were validated using an independent spatially resolved glomerular-specific transcriptome dataset from the GeoMx digital spatial analyzer. Upregulated gene sets in the GeoMx dataset showed a significant increase in MCD, MN, and DKD module scores in the dataset of this invention. Figure 17 Conversely, gene sets with reduced expression showed significantly lower module scores in MCD, MN, IgAN, and DKD. These results confirm that the transcriptomic data of this invention are similar to those of spatial transcriptomic profiles. Figure 18 ).
[0170] Experimental Results 5. Expression of disease-specific genes in podocytes and classification of podocyte cell subclusters Considering the crucial role of podocytes in the pathophysiology of proteinuric glomerular diseases, the gene expression patterns of podocyte clusters were analyzed in detail. First, the expression of DEG (depleted DEG expression) in podocytes of controls and each disease group was compared. Figure 19 ).
[0171] As a result, most of the genes with reduced expression showed characteristics of reduced expression in all four diseases (n = 116) or reduced expression specifically in DKD (n = 185).
[0172] Specifically, the co-regulated genes are associated with the regulation of cell migration and the suppression of the immune system. Figure 20 The above results are consistent with the increased inflammatory response in the disease group. Figure 21 Furthermore, genes associated with the regulation of the Wnt signaling pathway, which play important roles in exacerbating podocyte injury and dysfunction as well as the development of proteinuria, are also co-expressed with reduced expression. Among these genes, SEMA5A and NKD1 are known to activate the Wnt signaling pathway when their gene expression is reduced. Genes specifically reduced in DKD have been shown to be involved in the structure, development, and differentiation of podocytes. Figure 20 ).
[0173] Increased expression of gene modules showed a disease-specific trend. Figure 22The above results are consistent with the increased gene expression and disease specificity in Experiment 2. This further confirms the correlation between upregulated genes and disease specificity. Figure 8 Specifically, among the genes with increased specific expression in MN (n = 41), many are related to EMT, while in IgAN (n = 31), many are related to cell adhesion. Figure 23 The above results indicate that IgAN may be associated with podocyte adhesion disorders. Furthermore, it was confirmed that the expression of several DEGs associated with slit septum (SD), regeneration, detachment, and EMT status was increased in podocytes in a disease-specific manner. Figure 24 TJP1 and MAGI2, markers of slit septum (SD), showed persistently reduced expression in the disease cohort. Furthermore, VCL, which regulates podocyte morphology and localizes ZO-1 to the plasma membrane to maintain the glomerular barrier, also showed reduced expression in glomerular disease. In MCD, the expression of DEGs (n = 19), namely MYH9, SRGAP1, TCF21, and SLIT2, involved in podocyte adhesion, was increased. In MN, specifically increased expression of GADD45A, VIM, and CDH6, which are associated with EMT, was confirmed. In DKD podocytes, the expression of genes involved in regeneration, including PAX8, was increased.
[0174] Podocyte clusters were clustered into 3 subclusters (sub-clusters) and annotated using marker genes. Figure 25 Within podocyte endocytosis clusters, the expression of genes associated with the CUBAM complex, such as LRP2, CUBN, CLCN5, and PRKCA, is increased. When podocytes are sub-clustered in published external snRNA-seq data in the same manner as in this invention, clusters similar to podocyte endocytosis clusters can be identified.
[0175] Comparison of genes related to podocyte endocytosis and podocyte-related genes confirmed that in the context of podocyte endocytosis clusters, the expression of podocyte dedifferentiation-related genes increased, while the expression of genes involved in cell cycle repression (CDKN1B) decreased. Furthermore, the module scores of cell proliferation-related genes were significantly higher in podocyte endocytosis clusters.
[0176] Furthermore, module scores of genes specifically expressed in podocyte endocytic clusters showed a trend proportional to the severity of proteinuria. Figure 26 Specifically, in MCD and MN, the module scores containing podocyte endocytosis cluster-specific genes were significantly higher compared to other glomerular disease groups or controls. Figure 27 However, gene module scores were inconsistent with podocyte endocytosis capacity, and it was confirmed that podocyte endocytosis was significantly higher in IgAN.
[0177] To identify the reasons for the discrepancy between the expression of endocytosis-related genes and the actual endocytosis phenomenon, the expression of podocyte endocytosis-related genes in the glomerular disease group was analyzed.
[0178] The results confirmed that genes associated with the CUBAM complex, including LRP2 and CUBN, were primarily highly expressed in the MCD, while cell proliferation-related genes were highly expressed in the MN. In IgAN and DKD, which contained lower module scores for podocyte endocytosis marker genes, increased expression of epidermal growth factor receptor (EGFR) pathway-related genes such as ERBB4 and NRG3 was confirmed. Consequently, the EGFR pathway gene module score was significantly higher in IgAN compared to MN and MCD.
[0179] Similar results were also confirmed in RNA in situ hybridization experiments. Podocyte endocytosis assessed by LRP2 was significantly more pronounced compared to IgAN, DKD, or controls. Figure 28 The above results indicate that endocytosis in podocytes may play a protective role against proteinuria. In other words, increased podocyte endocytosis and decreased expression of endocytosis-related genes in IgAN suggest impaired podocyte endocytosis. In this case, since endocytosis is important for regulating cell surface receptors, including EGFR, it is believed that impaired podocyte endocytosis leads to activation of the EGFR signaling pathway.
[0180] Experimental Results 6. Analysis of disease-related gene expression in TGF-β-induced myofibroblasts Based on known marker genes, stromal cell clusters, including VSMCs (vascular smooth muscle cells) and fibroblasts, were classified into 12 cell subclusters and annotated ( Figure 29 ).
[0181] The results confirmed that the expression of TGF-β signaling-related genes was generally increased in stromal cells of patients with glomerular disease. Figure 30 In stromal cell subclusters, TGF-β signaling-related genes were significantly increased in myofibroblast clusters. Figure 31 Furthermore, trajectory analysis confirmed that all types of glomerular diseases are associated with the transition from fibroblasts to myofibroblasts. Figure 32 Therefore, it is believed that the increased expression of TGF-β signaling-related genes occurs during cellular transformation.
[0182] Specifically, trajectory analysis results confirm that many genes related to mesenchymal cell differentiation are present in the early stages, while the final cell clusters contain many genes related to myofibroblast activity, such as extracellular structural tissues ( Figure 33Compared with controls, the expression of genes associated with myofibroblast enrichment, as well as myofibroblast-related genes SULF1, NOX4, and COL1A1, was increased in all glomerular disease groups. Furthermore, a significantly increased proportion of myofibroblast clusters was confirmed in all glomerular disease groups compared with controls.
[0183] In heatmaps generated using myofibroblast-related cells (e.g., fibroblasts, medullary fibroblasts, adaptive fibroblasts, and myofibroblasts) and glomerular disease DEG, modules that were co-upregulated across disease groups (module 4) were... Figure 34 It contains myofibroblast marker genes and / or TGF-β signaling-related genes. In fact, many biological functions related to myofibroblasts, such as extracellular matrix organization, are contained in module 4. Figure 35 In particular, module 1 is highly expressed in DKD, and module 1 contains many genes associated with calcium ion transmembrane transport. Figure 35 Here, calcium transport dysregulation is known to be associated with the progression of renal fibrosis. Module 2 is highly expressed in the MCD, and module 3 is highly expressed in the MN. Furthermore, modules 2 and 3 also contain many genes associated with cell-matrix adhesion and integrin-mediated signaling pathways. Figure 34 In this invention, the gene set module scores of myofibroblasts are significantly increased in glomerular diseases, particularly in MN and DKD. Furthermore, these module scores are significantly positively correlated with cell clusters (glomerular filtration rate, GFR). Figure 36 ).
[0184] The above results indicate that myofibroblasts are a common cell type in glomerular diseases, and that these cells are closely associated with decreased renal function.
[0185] Experimental Results 7. Analysis of Disease-Related Genes in Endothelial Cells Using existing marker genes, endothelial cell clusters were classified into 11 cell subclusters and annotated, and the DEG (deterministic genetic marker) of each cell cluster was analyzed. Figure 37 and Figure 38 ).
[0186] Specifically, genes with increased specific expression in MCD and MN were analyzed. Figure 39 These genes are those associated with TGF-β signaling and interferon-α response. Figure 40 According to gene module scores, TGF-β signaling-related genes were most highly expressed in MN, followed by high expression in MCD and DKD. Figure 41On the other hand, genes associated with the interferon-α response were most highly expressed in MCD, followed by high expression in MN and DKD. Both signaling pathways were increased in the glomerular disease group compared to the control. In the case of cellular subclusters, both signaling pathways were most highly expressed in endothelial cells. Figure 42a and Figure 42b In particular, the expression of the interferon-α response gene is increased in MCD (). Figure 43 ).
[0187] Experimental Results 8. Disease-specific gene analysis in proximal tubules Using existing marker genes, proximal tubule (PT) clusters were classified into 14 cellular subclusters, and then the DEG (deterministic genetic marker) of each cellular cluster was analyzed. Figure 44 and Figure 45 ).
[0188] As a result, the expression of genes related to transporter activity in the proximal tubule (PT) was generally reduced across all disease groups. Specifically, in DKD, 199 genes (27% of the total) were reduced. These genes were analyzed to be related to fatty acid metabolism processes. The above results were not specific to the constituent cell types of the glomerulus and were similar to the DKD-specific gene expression results.
[0189] Compared with the control group, the expression of genes associated with the Wnt / β-catenin signaling pathway was also increased in the glomerular disease group. Figure 46 The above results are similar to those showing reduced expression of activated Wnt signaling-related genes (SEMA5A, NKD1) in podocytes. This signaling pathway is known to be unactivated under normal conditions but activated under injury conditions. Specifically, activation of this pathway is known to protect the kidneys in acute kidney injury but promote disease progression in chronic kidney disease. In this invention, compared to controls, CTNNB1 gene expression was increased in the glomerular disease group, and FN1 and MMP7 (known regulators of the Wnt / β-catenin signaling pathway in chronic kidney disease) expression was increased in DKD. Furthermore, genes involved in proliferation via the Wnt / β-catenin signaling pathway (MYC, CCND1) expression was increased in MN, while the expression of negative regulators of the Wnt / β-catenin signaling pathway (INVS) was decreased in MN, IgAN, and DKD. Figure 47 ).
[0190] DEG (expressed increased in the glomerular disease group) Figure 48 Genes associated with proximal tubule endocytosis, hypertrophy, injury, and adaptation were increased in the glomerular disease group. Figure 49Specifically, the components of the CUBAM complex, LRP2, CUBN, and DAB2 (responsible for protein endocytosis in the proximal tubule), showed significantly high expression in the MCD. PT hypertrophy marker genes (e.g., PPARA, HNF4A) that may be involved in the next step of PT endocytosis showed increased expression in both the MCD and IgAN compared to the control. PT damage marker genes (TINAG, SPP1, COL18A1, HAVCR1, etc.) showed increased expression in the MN, while PT adaptation marker genes (SOX4, CDH6, CD24, PROM1) showed significantly increased expression in the DKD. Examination of the actual proportions of cell types within the proximal tubule revealed a significant increase in adapted PT cells in both the MN and DKD.
[0191] Furthermore, trajectory analysis confirmed the progression from normal proximal tubules to adaptive proximal tubules. In particular, the presence of stage 3 PT in DKD was closely associated with lesion (…). Figure 50 Furthermore, it was confirmed that the expression of genes highly expressed in the adaptive state PT (e.g., AGBL4, KCNT2, KAZN, RHEX) was also increased along the trajectory.
[0192] Experimental Results 9. Discussion This invention is an analysis of the mononuclear transcriptomes of 262,984 constituent cells obtained from glomerular tissue from 28 patients. These results represent the most extensive single-cell source to date for studying biopsy-diagnosed glomerular diseases. Through transcriptomic analysis of various renal cell clusters, including glomerular cells, this invention clearly elucidates changes at the gene level in glomerular diseases.
[0193] This invention allows for the identification of commonalities and differences in gene expression patterns across various glomerular diseases, and by incorporating cell clusters to reduce the number of less severely affected subjects, it enables the comparison of transcriptomic changes across cell types at relatively early stages of the disease. Therefore, the results according to this invention may contribute to understanding the pathophysiological mechanisms specific to glomerular diseases, and it is anticipated that this may help in the discovery of pathological pathways involved in the progression of chronic kidney disease (CDK), as well as biomarkers for diagnosis or treatment.
[0194] In this invention, increased gene expression forms unique modules associated with the disease, while decreased gene expression forms modules based on cell clusters. These results suggest that specific pathophysiological pathways in glomerular diseases may affect the kidney regardless of cell type. Furthermore, the affected cells imply that the unique functions of each cell type may degenerate in each different glomerular disease. Modules with increased expression specifically in MCD contain a large number of transport-related genes. This is thought to be a compensatory mechanism arising from the proximal tubule (PT) when podocyte slit septum (SD) damage prevents metabolite filtration. Modules containing genes with increased expression specifically in MN consist of genes involved in EMT and interferon-γ responses, suggesting an association of EMT in MN pathogenesis following an autoimmune-induced inflammatory response to the PLA2R antigen. Modules containing genes with increased expression specifically in IgAN contain a large number of genes associated with aldosterone-mediated sodium reabsorption and the MAPK signaling pathway. Based on reported findings, in IgAN patients with 1g or more of proteinuria per day, the MAPK / ERK signaling pathway is activated in mesangial cells, and activation of the renin-angiotensin-aldosterone system (RAAS) must precede activation of this signaling pathway. In this invention, modules specifically increased in expression in IgAN include the aldosterone receptor (NR3C2) and the gene that converts cortisol to an inactive form (HSD11B2).
[0195] In this invention, a "transition" cell cluster located between parietal epithelial cell (PEC) clusters and podocyte clusters was identified. Podocytes are epithelial cells that dedifferentiate under injury conditions, which induces podocyte foot process loss and EMT. Parietal epithelial cells share the same origin as podocytes and possess proliferative capacity, and are considered progenitor cells that can replace podocytes under injury conditions. Under normal conditions, parietal epithelial cells are known to be activated and differentiate into podocytes upon podocyte detachment. However, under pathological conditions, various signaling pathways are activated in parietal epithelial cells, leading to abnormally proliferating parietal epithelial cells, which may induce glomerulosclerosis. In this invention, the results of SCENIC analysis of transcription factors changing during activation identified transcription factors specifically increased in all glomerular diseases (MN, IgAN, and DKD) except for MCD. Figure 15The above results are consistent with existing methods and findings that differentiate MCD from early focal segmental glomerulosclerosis (FSGS) by activating PECs. NFIB and ESRRB, which are expressed at particularly increased levels during the transition, are known to play important roles in cell differentiation and proliferation, respectively. According to previous studies, GATA3 is involved in maintaining glomerular homeostasis and responding to injury in mesangial cells. Increased TFDP2 expression in PECs is involved in inhibiting cell cycle progression, and NOTCH has been confirmed to regulate cell cycle progression, indicating an interaction between the two transcription factors. The transcription factors identified in this invention may determine the reversibility of glomerular diseases and are considered potential therapeutic targets in the future.
[0196] In this invention, LRP2 and CUBN, involved in endocytosis, are specifically increased in the proximal tubule (PT). These results were also reproduced in external mononuclear transcriptome analysis of patients with chronic kidney disease (CKD). Recent studies have reported that podocytes increase endocytosis to maintain glomerular filtration integrity in proteinuria, and the CUBAM complex plays a crucial role in this process. In this invention, module scores of genes involved in cell proliferation are increased in the proximal tubule cell clusters, suggesting that increased gene expression may indicate podocyte dedifferentiation due to inflammation. Furthermore, in this invention, comparisons of gene expression involved in endocytosis in each glomerular disease confirmed that the expression of EGFR-related genes known to promote podocyte injury is further increased in IgAN and DKD. Since IgAN and DKD are generally more chronically progressive diseases compared to MN or MCD, these results suggest that the characteristics of dedifferentiated podocytes exhibiting endocytosis may be associated with reversible podocyte injury. Furthermore, this implies that these results are relevant to the clinical features of glomerular diseases.
[0197] It is known that activated myofibroblasts induce excessive accumulation of extracellular matrix, thereby inducing the progression of renal fibrosis. In this invention, the transformation of fibroblasts into myofibroblasts is confirmed, and the TGF-β signaling pathway is involved in this process. As confirmed at the genetic level, the increase in myofibroblasts in glomerular diseases is a major pathological mechanism of fibrosis. Furthermore, the samples used in this invention were obtained from patients who had never exhibited a reduction in cell clusters. Therefore, the results of this invention, namely the positive correlation between increased expression of marker genes in myofibroblasts and decreased glomerular filtration rate, indicate that renal fibrosis may occur even in the early stages of kidney disease and may contribute to the decline in renal function.
[0198] In the endothelial cell clusters of MN and MCD, the expression of genes associated with TGF-β signaling and interferon-α response pathways was increased. The TGF-β signaling-related gene module score was highest in MN, indicating that MN endothelial cells are influenced by TGF-β signaling. The increased expression of TGF-β signaling-related genes in MN endothelial cells is consistent with the histological finding of increased glomerular basement membrane thickness. In MCD and MN, the expression of MHC molecule-related genes was increased. Typically, due to the lack of co-stimulatory molecules such as CD80 or CD86 in endothelial cells, it is difficult to induce activation of naïve T cells, and T cells with antigen exposure experience are known to be preferentially activated. Therefore, the results of this invention suggest that T cell activation may potentially be involved in the pathogenesis of nephrotic syndrome. Furthermore, in the case of MCD, the expression of interferon-α response genes is increased, thus it is expected that the steroid response will be well induced compared to other glomerular disease groups.
[0199] This invention has several limitations.
[0200] First, since controls are obtained from normal tissue adjacent to the tumor in patients with renal cell carcinoma, the characteristics of the controls may reflect the pathophysiology of the specific disease. Therefore, by collecting tissue before renal artery clipping using a biopsy gun, potential ischemic injury is minimized, thereby minimizing bias. Furthermore, partial validation analysis using external spatial transcriptomic data, including normal controls from donated kidney tissue, supports the results of this invention. Second, compared to existing mononuclear transcriptomic analyses, the number of immune cells analyzed is smaller, thus limiting the analysis of cross-signaling between systemic immune cells and renal resident cells in this invention. Third, the results of this invention are transcriptomic analysis results. Therefore, insights into the pathophysiological changes in glomerular diseases can be improved by including disease-specific proteomics or epigenomic profiling. Finally, single-cell level tissue data may be affected by the location of the biopsy target region due to the difficulty in obtaining renal cortex at the same scale.
[0201] In summary, this invention provides a comprehensive mononuclear transcriptome dataset for renal biopsy tissue analysis using MCD, MN, IgAN, and DKD. The results according to the invention provide new insights into cell-specific or disease-specific transcriptomic changes constituting the kidney. Therefore, the results according to the invention are considered potentially useful as biomarkers for diagnosis or treatment in the future.
Claims
1. A composition for diagnosing kidney disease, comprising a reagent for measuring the mRNA or protein expression level of any gene selected from the group consisting of i) to v): i) Selected from any gene from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7 and combinations thereof; ii) Selected from any gene among SPP1, VIM, TRIO, DST, TAPBP, IFNAR2 and combinations thereof; iii) Selected from any gene of HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5 and combinations thereof; iv) Any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, or combinations thereof; or v) Combinations of i) to iv) above.
2. The composition for diagnosing kidney disease according to claim 1, wherein the composition further comprises a reagent for measuring the expression level of any gene selected from TPM2, MICAL2, TJP1, ANXA2, DMD, CORO2B, SMAD3, NR4A1, LIMA1, ESYT2, SHB, SAMSN1, SPRED2, IRAK3, IKBKB, NFKBIA, FAAH, ACCA1, ACOX1, PTPN1, PTPRJ, NPR1, CDK6, HADHB, ETFDH, RAP1GAP, RGS6, HSD17B4, DAAM2, ROCK2, RAGEF5, TBC1D1, THBS1, ERBB2, STAT3, and combinations thereof.
3. The composition for diagnosing kidney disease according to claim 1, wherein the reagent for measuring the mRNA expression level of the gene is a primer or probe that specifically binds to the nucleic acid sequence of the gene according to claim 1 or 2.
4. The composition for diagnosing kidney disease according to claim 1, wherein the reagent for measuring the expression level of the gene protein is an antibody, ligand, or aptamer that specifically binds to the protein encoded by the gene according to claim 1 or 2.
5. The composition for diagnosing kidney disease according to claim 1, wherein, compared with a control, the expression of mRNA or protein of any of the genes in claims 1 (i) to (v) is increased in the kidney disease.
6. The composition for diagnosing kidney disease according to claim 5, wherein, compared with a control, the expression of the mRNA or protein of the gene of claim 2 is reduced in the kidney disease.
7. The composition for diagnosing kidney disease according to claim 1, wherein the kidney disease is minimal change disease (MCD), membranous nephropathy (MN), immunoglobulin A nephropathy (IgAN), or diabetic nephropathy (DKD).
8. A kit for diagnosing kidney disease, comprising the composition of any one of claims 1 to 7.
9. The kit for diagnosing kidney disease according to claim 8, wherein the kit is a polymerase chain reaction (PCR) kit, a DNA chip kit, an enzyme-linked immunosorbent assay (ELISA) kit, or a protein chip kit.
10. A method for providing information for diagnosing kidney disease, comprising: a) In samples isolated from the subject, measure the mRNA or protein expression level of any gene selected from groups i) to v) below, and the gene vi) below; and b) when the mRNA or protein expression level of any gene selected from groups i) to iv) below is increased compared to the normal control, and the mRNA or protein expression level of the gene vi) below is decreased compared to the normal control, diagnose kidney disease: i) Selected from any gene from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7 and combinations thereof; ii) Selected from any gene among SPP1, VIM, TRIO, DST, TAPBP, IFNAR2 and combinations thereof; iii) Selected from any gene of HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5 and combinations thereof; iv) Any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, or combinations thereof; or v) combinations of i) to iv) above; and vi) Select any gene from the group consisting of TPM2, MICAL2, TJP1, ANXA2, DMD, CORO2B, SMAD3, NR4A1, LIMA1, ESYT2, SHB, SAMSN1, SPRED2, IRAK3, IKBKB, NFKBIA, FAAH, ACCA1, ACOX1, PTPN1, PTPRJ, NPR1, CDK6, HADHB, ETFDH, RAP1GAP, RGS6, HSD17B4, DAAM2, ROCK2, RAGEF5, TBC1D1, THBS1, ERBB2, STAT3, and combinations thereof.
11. The method of providing information for diagnosing kidney disease according to claim 10, wherein the method of providing information further comprises c) classifying the kidney disease.
12. The method for providing information for diagnosing kidney disease according to claim 11, wherein the gene with increased expression level compared to a normal control in claim 10 (b) is: When the gene i) is present, kidney disease is classified as minimal change disease (MCD). When the gene is present in ii), kidney disease is classified as membranous nephropathy (MN). When the gene iii) is present, the kidney disease is classified as immunoglobulin A nephropathy (IgAN), and / or When the gene iv is present, kidney disease is classified as diabetic nephropathy (DKD).
13. The method of providing information for diagnosing kidney disease according to claim 10, wherein the sample is tissue or cells isolated from a subject.
14. A biomarker for minimal change disease (MCD) comprising any gene selected from SLC13A1, SLC36A2, SLC13A3, SLC16A19, SLC22A6, SLC22A7, and combinations thereof.
15. A biomarker for membranous nephropathy (MN) comprising any gene selected from SPP1, VIM, TRIO, DST, TAPBP, IFNAR2, and combinations thereof.
16. A biomarker for immunoglobulin A nephropathy (IgAN) comprising any gene selected from HSD11B2, NR3C2, MAGI1, MAGI2, ERBB4, EFNA5, and combinations thereof.
17. A biomarker for diabetic nephropathy (DKD) comprising any gene selected from SCIN, TMSB4X, ST6GAL1, GNE, and combinations thereof.
